Perspectives

Know Your Guidelines Series: The ACG Practice Guideline on Gastroparesis

Authors: Samantha A. Whitwell, MD, Christian Salcedo, MD, Hira Imran, MD, Christopher D. Jackson, MD

Abstract

Gastroparesis (GP) is a disorder of gastric motility characterized by subjective and objective findings of delayed gastric emptying without evidence of gastric outlet obstruction. Symptoms of GP can include nausea, vomiting, early satiety, and abdominal pain, all of which can significantly influence the quality of life of a patient. The age-adjusted prevalence of definite GP was 9.6/100,000 population for men and 38/100,000 for women.1 Moreover, GP contributes to frequent hospitalizations and overall healthcare burden, warranting further research for diagnostic approaches and treatment options.
Posted in: Gastroenterology56

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Jung HK, Choung RS, Locke GR 3rd, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology 2009;136:1225–1233.
 
2. Camilleri M, Kuo B, Nguyen L, et al. ACG clinical guideline: gastroparesis. Am J Gastroenterol 2022;117:1197–1220.
 
3. Bharucha AE, Batey-Schaefer B, Cleary PA, et al. Delayed gastric emptying is associated with early and long-term hyperglycemia in type 1 diabetes mellitus. Gastroenterology 2015;149:330–339.
 
4. Calles-Escandon J, Koch KL, Hasler WL, et al. Glucose sensor-augmented continuous subcutaneous insulin infusion in patients with diabetic gastroparesis: an open-label pilot prospective study. PLoS One 2018;13:e0194759.
 
5. Bharucha AE, Kudva Y, Basu A, et al. Relationship between glycemic control and gastric emptying in poorly controlled type 2 diabetes. Clin Gastroenterol Hepatol 2015;13:466–476.e1.
 
6. Olausson EA, Störsrud S, Grundin H, et al. A small-particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: a randomized controlled trial. Am J Gastroenterol 2014;109:375–385.
 
7. Ganzini L, Casey DE, Hoffman WF, et al. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993;153:1469–1475.
 
8. Parkman HP, Van Natta ML, Abell TL, et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA 2013;310:2640–2649.
 
9. Roldan CJ, Chambers KA, Paniagua L, et al. Randomized controlled double-blind trial comparing haloperidol combined with conventional therapy to conventional therapy alone in patients with symptomatic gastroparesis. Acad Emerg Med 2017;24:1307–1314.
 
10. Carlin JL, Lieberman VR, Dahal A, et al. Efficacy and safety of tradipitant in patients with diabetic and idiopathic gastroparesis in a randomized, placebo-controlled trial. Gastroenterology 2021;160:76–87.